1. Without prejudice to other Community legislation, in particular Regulation (EC) No 258/97 of the European Parliament and the Council (4), and subject to paragraphs 2 and 3 of this Article, consent shall be given by the competent authorities of the United Kingdom to the placing on the market of the following product, notified by Novartis Seeds Inc. (Ref. C/GB/96/M4/1):
grains of genetically modified maize line Bt-11 containing:
(a) a synthetic version of the cryIA (b) gene derived from Bacillus thuringiensis subsp. kurstaki strain HD1 under the control of a 35S promoter from Cauliflower Mosaic Virus, and IVS 6 intron from the maize alcohol dehydrogenase gene and the nopaline synthase terminator sequence of Agrobacterium tumefaciens, and
(b) a synthetic version of the pat gene derived from Streptomyces viridochromogenes under the control of a 35S promoter from Cauliflower Mosaic Virus, an IVS 2 intron from the maize alcohol dehydrogenase gene and the nopaline synthase terminator sequence of Agrobacterium tumefaciens.
2. The consent shall cover grains from progenies derived from crosses of maize line Bt-11 with any traditionally bred maize imported into the Community.
3. The consent shall cover the placing on the market of the product to be used as any other maize grain but not for cultivation.